Medical Device Adaptive Update

The Layer in Question

Medical-device participants integrate runtime-signed adaptation artifacts that have been certified through sandbox pre-activation against a declared change envelope. Each adaptation activation admits through composite admissibility - FDA authority for regulated changes within the cleared PCCP, hospital authority for institutional configuration, OEM authority for device-specific calibration, and notified-body authority for EU MDR-governed deployments. Cascade-deactivation handles the realities that medical-device adaptation actually faces: an adaptation may need to be revoked because of a post-market signal, superseded by a newer version with stronger evidence, or scoped down because a downstream dependency was itself revoked. Federated skill training supports cross-hospital experience integration without requiring patient-level data to leave any institution's boundary.

Authority composition structures map cleanly to medical-device reality. FDA authority governs regulatory adaptation within the cleared PCCP; the agency does not need to re-clear every retraining cycle, but every retraining cycle needs to operate against a declared change envelope the agency has already accepted. OEM authority governs device-specific adaptation - sensor recalibration, hardware-revision-specific behavior, firmware corrections. Hospital authority governs institutional adaptation - integration with the local EHR, formulary-specific defaults, workflow customization. Professional-society authority - the kind that AHA, ACC, ASCO, and others already exert through guideline updates - governs clinical-practice adaptation. The architecture supports the multi-authority reality of medical-device adaptation rather than collapsing it into a single vendor's update channel.

Why Vendor-Specific Patterns Hit a Ceiling

Current medical-device adaptation depends on a brittle composition of FDA-mandated 510(k) update cycles, vendor-specific update mechanisms (each with its own signing, distribution, and rollback semantics), and hospital-specific update procedures (each with its own change-advisory-board cadence, validation protocol, and downtime window). The combined operation faces structural limitations that the AI/ML-Based SaMD Action Plan explicitly identifies: cycle latency that prevents adaptive models from incorporating real-world performance data on a clinically meaningful timescale, vendor lock-in that prevents hospitals from federating learning across heterogeneous device fleets, and audit complexity that makes adverse-event review (the kind FDA's MAUDE database depends on) prohibitively expensive when an event spans multiple update generations across multiple vendors.

Architectural spatial-adaptation produces structural improvement against each of these. Runtime-signed artifacts support continuous adaptation under credentialed authority - a retraining cycle that operates within the cleared PCCP can deploy to the field without re-traversing the 510(k) pathway, but every deployment carries the credential chain that lets FDA, the notified body, and the hospital each verify that the change was within the declared envelope. Sandbox pre-activation supports adaptation safety the way nuclear and aviation industries have practiced it for decades: a candidate adaptation runs against a curated representative dataset, and its declared performance against that dataset is what authorizes activation. Cascade-deactivation supports rapid revocation that mirrors the FDA Class I recall timelines that current vendor-specific mechanisms struggle to meet.

EU MDR Article 27 and the related UDI obligations add a parallel set of requirements that the same primitive answers. Each adapted artifact carries a UDI-DI consistent with its underlying device identification, each material change is recorded against the manufacturer's technical documentation, and the post-market surveillance plan that Annex III of the MDR requires is generated as a structural output of the architecture rather than as a separately maintained document set. Notified bodies conducting unannounced audits or post-market surveillance reviews query the same record the manufacturer relies on operationally, and the divergence that current paper-and-spreadsheet QMS systems create between operational and audit views simply does not arise.

How This Plugs Into Existing Operations

Each adaptation activation enters the runtime as a credentialed event with full FDA-aware audit lineage. The activation record links the deployed artifact to the cleared PCCP, the sandbox pre-activation evidence, the declared change envelope, and the chain of authority that authorized deployment at this institution. Cross-hospital operations - the kind that academic medical center networks, IDNs, and federated research consortia already conduct - admit through declared hospital federation, with each institution publishing the adaptations it accepts and the authorities it recognizes. Adversarial actions, including adaptation tampering, adaptation substitution, and integrity attacks against the update channel, surface as credentialed integrity events rather than as silent compromises that only show up in retrospective forensic review.

Federated skill training supports cross-hospital experience integration in a form that aligns with HIPAA, GDPR, and the increasingly active state-level patient-data regulations. Model updates derive from federated gradient aggregation, the gradient contributions are themselves credentialed events, and the resulting adaptation carries provenance back to the participating institutions without ever propagating patient-level data. Real-world performance monitoring, which the AI/ML-Based SaMD Action Plan identifies as a central pillar of adaptive SaMD oversight, becomes a first-class architectural output rather than a bespoke per-vendor pipeline.

The ML lifecycle that the Action Plan describes - data management, model training, model evaluation, deployment, and monitoring - maps onto the architecture phase by phase. Data management runs under hospital and federation authorities with the IRB-aligned scoping that human-subjects research already requires. Model training runs under OEM authority with the predetermined-change-control envelope that PCCP authorizes. Model evaluation runs through sandbox pre-activation, with declared performance against curated reference datasets composing into the activation decision. Deployment runs under composite admissibility, with each institution's acceptance an explicit authority declaration. Monitoring runs continuously, producing the real-world performance evidence that closes the loop into the next training cycle. The architecture does not invent the lifecycle; it gives the lifecycle a runtime surface that auditors, operators, and regulators can each compose against.

FDA's Predetermined Change Control Plan framework integrates through declared admissibility profiles. The PCCP is, in architectural terms, a declaration of which adaptations the manufacturer has pre-authorized and under what conditions; the spatial-adaptation primitive enforces that declaration at runtime and produces audit evidence sufficient for both FDA review and notified-body MDR conformity assessment. Architectural adaptation supports PCCP-eligible continuous learning while maintaining structurally supported regulatory audit, including the post-market surveillance obligations EU MDR Article 27 places on manufacturers and notified bodies.

The five governance properties specified in U.S. provisional application 64/049,409 — authority-credentialed observation of each sandbox pre-activation result, evidential weighting under FDA-recognized performance methodology, composite admissibility across OEM, hospital, and notified-body authorities, governed actuation of each adaptation activation, and lineage-recorded provenance back through every gradient contribution — compose into the regulatory-aware adaptation surface as a single chain. Severing any property collapses the surface back into vendor-specific update mechanics that the PCCP envelope cannot meaningfully enforce.

What Adoption Unlocks

Medical-device OEMs gain structurally supported adaptive operations that materially shorten the path from real-world performance signal to deployed improvement, without compromising the regulatory posture that distinguishes a medical device from a consumer-electronics analog. Hospitals gain structurally supported adaptation governance that lets clinical leadership, biomedical engineering, IT, and compliance each exert their legitimate authority over what runs in their environment. FDA gains structurally supported adaptation oversight that scales with the volume of AI/ML-based SaMD entering the market. Patient safety gains structurally supported audit evidence that turns adverse-event review from an archaeology project into a query against a coherent record.

The architecture also supports medical-device evolution on the timescales the field is actually moving. As emerging adaptation patterns mature - AI-augmented adaptation that learns from real-world performance, federated medical learning across institutional boundaries, real-world-evidence-driven adaptation that closes the loop between MAUDE-style post-market signals and deployed behavior, ambient-intelligence medical adaptation that integrates with the broader hospital environment - the architecture admits the new patterns through declared specification rather than re-architecture.

The regulatory convergence is already visible. PCCP, EU MDR, and the successor frameworks now in draft at MHRA, PMDA, and Health Canada all converge on the same architectural requirement: continuous improvement under continuous governance, with traceability sufficient for both pre-market clearance and post-market surveillance. The IMDRF Software as a Medical Device working group's harmonization documents, the ISO/IEC 5338 AI system life cycle standard, and the ISO 13485 quality-management requirements that already govern medical-device manufacturing each impose part of the surface. Spatial adaptation is the runtime surface that surface has been waiting for.

The novel architectural claim worth recording is that runtime-signed adaptation, sandbox pre-activation, cascade-deactivation, and federated skill training compose into a single regulatory-aware substrate that supports AI/ML-based SaMD, traditional firmware updates for class II and class III devices, and the increasingly common hybrid devices that combine deterministic firmware with adaptive ML components. Each authority - FDA, notified body, hospital, OEM, professional society - composes against the same primitive without bilateral integration, and the resulting record is sufficient for adverse-event reconstruction, post-market surveillance reporting, and the kind of cross-institutional outcome research that has historically been gated on data interoperability rather than on clinical interest. That composition, end to end, is what no current vendor-specific update mechanism provides.